Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma (NCT03991962)

🧪 Interventions in This Study

• mFOLFIRINOX (DRUG)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Histologically confirmed pancreatic adenocarcinoma
2. Borderline resectable pancreatic adenocarcinoma or locally advanced pancreatic adenocarcinoma
3. No evidence of extrapancreatic disease on diagnostic imaging
4. No evidence of invasion into the duodenum or stomach, as determined by EGD/EUS
5. No prior treatment (chemotherapy, biological therapy, or radiotherapy) for pancreatic cancer
6. No prior treatment with oxaliplatin, irinotecan, fluorouracil, or capecitabine
7. ECOG Performance Status of 0-1
8. No other malignancy within past five years (exceptions include basal cell carcinoma of the skin, cervical carcinoma in situ, and non-metastatic prostate cancer)
9. No evidence of second malignancy at the time of study entry
10. No interstitial pneumonia or extensive and symptomatic interstitial fibrosis of the lung
11. No \> grade 2 sensory peripheral neuropathy
12. No uncontrolled seizure disorder, active neurological disease, or known CNS disease

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Yale University School of Medicine — New Haven, Connecticut

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Pancreatic Cancer

• A Study of Multiparametric Ultrasound Imaging Methods — Basking Ridge, New Jersey
• Alpha Radiation Emitters (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer — Gilbert, Arizona
• Safety and Efficacy of Endoscopic Ultrasound (EUS) Guided Radiofrequency Ablation (RFA) in the Treatment of Pancreatic Lesions — Houston, Texas
• Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations — Tampa, Florida
• A Study of the Life Changes Experienced by Patients With Pancreatic Cancer — New York, New York
• Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma — Aurora, Colorado

Explore by condition: All Pancreatic Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.